title: [New therapies in metastatic castration resistant prostate cancer].
abstract: Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.
authors.affiliation: Gustave-Roussy, département innovation thérapeutique et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
authors.forename: Constance
authors.initials: C
authors.lastname: Thibault
authors.affiliation: Gustave-Roussy, département innovation thérapeutique et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: christophe.massard@gustaveroussy.fr.
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000096:biosynthesis; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D019496:Cancer Vaccines
keywords: Abiraterone; Abiratérone; CRPC; Cabozantinib; Enzalutamide; MOSCATO